COCP Stock — Cocrystal Pharma Inc

Cocrystal Pharma Inc (COCP)

Updated October 16, 2026.

COCP is a Stock. Total return is 36328.6% over the past 18.5 years, 35646.1 points ahead of SPY at 682.5%.

Cocrystal Pharma is a biotechnology company focused on discovering and developing antiviral treatments for serious viral diseases, including influenza, norovirus, coronavirus variants, and hepatitis C, using structure-based drug design technology. The company has multiple candidates in clinical development, including CC-42344 for influenza (in phase 2a), CDI-988 for norovirus and coronavirus infections (in phase 1), and CC-31244 for hepatitis C (completed phase 2a), along with collaborations including a license agreement with Merck for influenza antivirals. The company does not currently distribute, making it suitable for investors focused on long-term capital appreciation in early-stage drug development rather than current income.

COCP performance versus SPY

Price and return data through 2026-10-16.

Total return is 36328.6% over the past 18.5 years, 35646.1 points ahead of SPY at 682.5%. Over the past year its total return — price change plus distributions reinvested — is -4.7%. Its deepest 1-year drawdown was 47.8%.

COCP key facts

Asset type

Stock

Asset class

Equity

Inception date

04/01/2008

Distribution frequency

None

Last close

$1.02 (as of 2026-10-16)

Market cap

$19,648,464

Average volume

22775.0

Payment date

01/24/2018

Beta

1.482

Payout ratio

0.0%

EPS

$-0.76

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

COCP risks and drawbacks

The deepest 1-year drawdown on record here is 47.8%.

Who may consider COCP — and who may not

It is a weaker fit for investors who need monthly cash flow (COCP does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on COCP

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions